probiotics for depression in cancer patients

Conditions: Depression; Anxiety Disorder; Probiotics; Gastrointestinal Cancer; Quality of Life; Chemotherapy

Summary: anxiety and depressive disorders are quite prevalent in the general population. in 2015, it was estimated that 3.6% of the world population (around 264 million individuals) live with depression and 4.4% (around 322 million) with anxiety, while in the recent years of the covid-19 pandemic, the prevalence of these disorders has significantly increased. according to the american psychiatric association, in 2013 depression was defined as a serious mental illness characterized by decreased mood lasting more than 15 days, a lack of interest, and (even) apathy to normal daily activities. depression, particularly in its severe form - the major depressive disorder (mdd), is the second leading cause of disability and the most common emotional disorder. recent research data indicate that this psychiatric disorder, as also similar neuropsychological conditions (parkinson's, autism, etc.) have, as their main substrate, a disturbance in the diversity of the gut microbiome. more specifically, it has been shown that there is a direct and bidirectional communication between gut and brain - the "gut-brain-axis". the gut, through its microbiome, communicates with the brain by means of neural, immunological, and metabolic pathways, either directly, through the vagus nerve or indirectly, either through the microbiome immunomodulation or the tryptophan pathway, or by the production of various neuroactive molecules. the disturbance in the diversity of the gut microbiome, termed dysbiosis, involves changes in the composition and the number of bacteria genera; and is causatively related to depression via the gut-brain axis. the transmission of nerve impulses, both via the hypothalamic-pituitary-adrenal axis and via the vagus nerve is disrupted by dysbiosis, leading to anxiety and depression, or, conversely, stressful conditions, more particularly emotional stress, which triggers an imbalance in the hypothalamic-pituitary-adrenal axis, leading to systemic immune responses and intestinal dysbiosis. this imbalance can clinically manifest with alterations in digestive tract function, knowledge accepted since the beginning of the previous century. nowadays, there is considerable evidence that the gut microbiome represents a novel anti-depressant and the term "psychobiotics" has been used to describe those species of probiotic bacteria excreting mental health benefits. certain bifidobacterium and lactobacillus species have already demonstrated, both experimentally and in clinical studies, their capability to improve mood, reduce anxiety, and enhance cognitive function. on these grounds, it is reasonable to raise the hypothesis that, by restoring the diversity of the gut microbiome, and thus enhancing the population of these specific probiotic species - termed 'psychobiotics', due to their specified functions, - could at least lead to an improvement in neuro-psychological disorders through gut-brain-axis remodeling.

based on the assumption that 1. at least one third of digestive cancer patients operated on - and probably more, when surgery is followed by chemotherapy sessions - suffer from anxiety and depression, 2. psychobiotics can beneficially modify the gut microbiome, 3. psychobiotics can improve the mental health of patients suffering from depression, and 4. there is no other study on the use of psychobiotics in anxiety and/or depression symptoms in patients operated on for digestive tract malignancies and subjected to chemotherapy thereafter the present study was designed to investigate the ability of a probiotic formulation containing bacteria with known psychobiotic properties to change the depression and anxiety status of digestive cancer patients undergoing chemotherapy postoperatively. this study will be a prospective, double-blind, randomized study against placebo in patients operated on for digestive cancer and undergoing chemotherapy. the study will be conducted in the 1st surgical department of the aristotle university of thessaloniki, at the ahepa university hospital of thessaloniki, greece, in collaboration with the outpatient surgical oncology unit. permission has already been obtained from the scientific council of the ahepa hospital (approval number: 313/4.7.2023). the oncologist involved in the study protocol will be responsible for randomization. she will inform the patients who meet the study entry criteria of the purpose of the study, and receiving their written consent after detailed information. patients having signed the informed consent will then be assigned at random \[in a 1:1 ratio\] to receive placebo or probiotic regime treatment, according to a computer-based table \[randomized.com\]. the randomization will be blinded to the study statistician, as well as to the physicians in contact with patients for interviews to facilitate the collection of answers to the questionnaires. sealed envelops will be used to ensure blinding. only the study coordinator will be aware of the content, having no further involvement with the patients. each patient, having signed the consent, will then receive a unique code-number, being a combination of the anatomical location of the tumor, the patient's serial number, a capital letter a or b - blindly indicating the treatment groups - and a small letter, \[a,b,c\] indicating the physician who contacts each patient. after patient aggrees to be included in the study, the demographic data that will be obtained in relation to each patient are: gender; age; body weight (in kilograms) and height (in meters) to calculate bmi; reported weight loss in kilograms since the disease diagnosis; marital status; smoking habits (no smoking or number of cigarettes/day); alcohol consumption (type and volume); and the possible use of tranquilizers \[mg of active substance\]. optionally, patients will give information as to their educational level (1st, 2nd, or 3rd grade), annual income (\ 30.001€/year); and health care insurance (public, private, both). from their medical records cancer type and anatomical localization; cancer stage (tnm classification); type of surgical intervention; and co-morbidity indices (charlson comorbidity index) will be obtained. additional information will be collated relating to the time lapse since diagnosis (in days); the time lapse from hospital discharge to starting chemotherapy (in days); and the time from starting chemotherapy to study entry (in days). the probiotic regime under testing is a combination of 4 psychobiotics: lactobacillus rhamnosus, bifidobacterium animalis subsp. lactis, bifidobacterium breve, and bifidobacterium longum, at a dose of 1.000.000.000/cfu. these for psychobiotics are the main ingredients of the commercially available formula lactolevure®, probiomood \[unipharma, athens, greece\], which also contains saffron and magnesium. this formula is marketed for "people with an anxious lifestyle who often suffer from symptoms such as low mood or fatigue as a result of stress". the placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. both will be identically standardized by the same pharmaceutical company \[uni-pharma, greece\]. patients will be administered the "treatment" or the placebo daily - one sachet twice a day, two hours after breakfast, for 30 consecutive days. at the follow-up appointment after treatment termination, patients will be required to return any remaining sachets which they forgot to take \[patients will be telephoned to remind a day before appointment). fifteen days after the start of treatment, there will be telephone contact (or a face-to-face contact if the new chemotherapy appointment coincides) for the purpose of a rough, out of the protocol assessment of the patient's condition by the same physician who conducted the initial interview; the purpose being to confirm that the patient is receiving the treatment and to un-officially obtain information on whether he/she is generally feeling better than previously. two follow up evaluations will be held 1 month and 3 months, after treatment begins. patients will be evaluated by means of standardized questionnaires - officially translated and validated in the greek language - for the quantification of depression, emotional state, anxiety, quality of life, physical weakness and pain.

Eligibility criteria:
inclusion criteria: * age \>18 and \<85 * histologically confirmed diagnosis of digestive tract malignancy, the tumor having been surgically resected and the patient currently undergoing chemotherapy sessions * informed consent obtained to participate in the study exclusion criteria: * not understanding the greek language * dementia * pre-existing psychiatric disorders * already receiving probiotic supplements (apart from yoghurt) * participation in another clinical trial * consumption of less than the 90% of treatment sachets/doses (verified by the sachets returned) * those having received during hospitalization other probiotic formulations

Keywords: randomized clinical trial gastrointestinal cancer chemotherapy psychobiotics depression anxiety quality of life